These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

512 related articles for article (PubMed ID: 28988501)

  • 1. Dermatofibrosarcoma protuberans and gastrointestinal stromal tumor as models for targeted therapy in soft tissue sarcomas.
    Koseła-Paterczyk H; Rutkowski P
    Expert Rev Anticancer Ther; 2017 Dec; 17(12):1107-1116. PubMed ID: 28988501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans.
    Maki RG; Awan RA; Dixon RH; Jhanwar S; Antonescu CR
    Int J Cancer; 2002 Aug; 100(6):623-6. PubMed ID: 12209598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dermatofibrosarcoma protuberans: recent clinical progress.
    McArthur G
    Ann Surg Oncol; 2007 Oct; 14(10):2876-86. PubMed ID: 17647063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current treatment options for dermatofibrosarcoma protuberans.
    Rutkowski P; Debiec-Rychter M
    Expert Rev Anticancer Ther; 2015; 15(8):901-9. PubMed ID: 26027711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225.
    McArthur GA; Demetri GD; van Oosterom A; Heinrich MC; Debiec-Rychter M; Corless CL; Nikolova Z; Dimitrijevic S; Fletcher JA
    J Clin Oncol; 2005 Feb; 23(4):866-73. PubMed ID: 15681532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-up.
    Ugurel S; Mentzel T; Utikal J; Helmbold P; Mohr P; Pföhler C; Schiller M; Hauschild A; Hein R; Kämpgen E; Kellner I; Leverkus M; Becker JC; Ströbel P; Schadendorf D
    Clin Cancer Res; 2014 Jan; 20(2):499-510. PubMed ID: 24173542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Dermatofibrosarcoma protuberans].
    Sanmartín O; Llombart B; López-Guerrero JA; Serra C; Requena C; Guillén C
    Actas Dermosifiliogr; 2007 Mar; 98(2):77-87. PubMed ID: 17397592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term results of treatment of advanced dermatofibrosarcoma protuberans (DFSP) with imatinib mesylate - The impact of fibrosarcomatous transformation.
    Rutkowski P; Klimczak A; Ługowska I; Jagielska B; Wągrodzki M; Dębiec-Rychter M; Pieńkowska-Grela B; Świtaj T
    Eur J Surg Oncol; 2017 Jun; 43(6):1134-1141. PubMed ID: 28365129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The importance of mutational status in prognosis and therapy of GIST].
    Comandone A; Boglione A
    Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging drugs for the treatment of gastrointestinal stromal tumors.
    Pilco-Janeta DF; García-Valverde A; Gomez-Peregrina D; Serrano C
    Expert Opin Emerg Drugs; 2021 Mar; 26(1):53-62. PubMed ID: 33645383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New targets and therapies for gastrointestinal stromal tumors.
    Wozniak A; Gebreyohannes YK; Debiec-Rychter M; Schöffski P
    Expert Rev Anticancer Ther; 2017 Dec; 17(12):1117-1129. PubMed ID: 29110548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted therapy for dermatofibrosarcoma protuberans.
    Abrams TA; Schuetze SM
    Curr Oncol Rep; 2006 Jul; 8(4):291-6. PubMed ID: 17254529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Target therapy of unresectable or metastatic dermatofibrosarcoma protuberans with imatinib mesylate: an analysis on 22 Chinese patients.
    Wang C; Luo Z; Chen J; Zheng B; Zhang R; Chen Y; Shi Y
    Medicine (Baltimore); 2015 May; 94(17):e773. PubMed ID: 25929918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis.
    Sjöblom T; Shimizu A; O'Brien KP; Pietras K; Dal Cin P; Buchdunger E; Dumanski JP; Ostman A; Heldin CH
    Cancer Res; 2001 Aug; 61(15):5778-83. PubMed ID: 11479215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Multicenter Phase II Study of Pazopanib in Patients with Unresectable Dermatofibrosarcoma Protuberans.
    Delyon J; Porcher R; Battistella M; Meyer N; Adamski H; Bertucci F; Guillot B; Jouary T; Leccia MT; Dalac S; Mortier L; Ghrieb Z; Da Meda L; Vicaut E; Pedeutour F; Mourah S; Lebbe C
    J Invest Dermatol; 2021 Apr; 141(4):761-769.e2. PubMed ID: 32956651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical development landscape in GIST: from novel agents that target accessory pathways to revisiting non-targeted therapies.
    Sankhala KK
    Expert Opin Investig Drugs; 2017 Apr; 26(4):427-443. PubMed ID: 28267385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic aberrations in imatinib-resistant dermatofibrosarcoma protuberans revealed by whole genome sequencing.
    Hong JY; Liu X; Mao M; Li M; Choi DI; Kang SW; Lee J; La Choi Y
    PLoS One; 2013; 8(7):e69752. PubMed ID: 23922791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic therapy of advanced/metastatic gastrointestinal stromal tumors: an update on progress beyond imatinib, sunitinib, and regorafenib.
    Mohammadi M; Gelderblom H
    Expert Opin Investig Drugs; 2021 Feb; 30(2):143-152. PubMed ID: 33252274
    [No Abstract]   [Full Text] [Related]  

  • 19. Using imatinib as neoadjuvant therapy in dermatofibrosarcoma protuberans: potential pluses and minuses.
    Johnson-Jahangir H; Sherman W; Ratner D
    J Natl Compr Canc Netw; 2010 Aug; 8(8):881-5. PubMed ID: 20870634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beyond standard therapy: drugs under investigation for the treatment of gastrointestinal stromal tumor.
    Alturkmani HJ; Pessetto ZY; Godwin AK
    Expert Opin Investig Drugs; 2015; 24(8):1045-58. PubMed ID: 26098203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.